JU INSIGHT Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy

By: Peter S. Kirk, MD, University of Washington, Seattle; Yair Lotan, MD, University of Texas Southwestern, Dallas; Homayoun Zargar, MD, PhD, Western Health, Melbourne, Australia; Adrian S. Fairey, MD, USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, University of Alberta, Edmonton, Canada; Colin P. Dinney, MD, MD Anderson Cancer Center, Houston, Texas; Maria C. Mir, MD, Fundacio Instituto Valenciano de Oncologia, Valencia, Spain; Laura-Maria Krabbe, MD, University of Münster, Germany; Michael S. Cookson, MD, University of Oklahoma College of Medicine, Oklahoma City; Niels-Erik Jacobson, MD, University of Alberta, Edmonton, Canada; Jeffrey S. Montgomery, MD, University of Michigan Health System, Ann Arbor; Nikhil Vasdev, MD, Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, United Kingdom, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Evan Y. Yu, MD, University of Washington, Seattle, Fred Hutchinson Cancer Center, Seattle, Washington; Evanguelos Xylinas, MD, Weill Cornell Medical College, Presbyterian Hospital, New York, New York; Wassim Kassouf, MD, McGill University, Health Center, Montreal, Quebec, Canada; Marc A. Dall’Era, MD, University of California at Davis, Davis Medical Center, Sacramento; Srikala S. Sridhar, MD, Princess Margaret Hospital, Toronto, Ontario, Canada; Jonathan S. McGrath, MD, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, United Kingdom; Jonathan Aning, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, United Kingdom; Shahrokh F. Shariat, MD, University of Texas Southwestern, Dallas, Weill Cornell Medical College, Presbyterian Hospital, New York, New York, Medical University of Vienna, Vienna General Hospital, Austria; Andrew C. Thorpe, MCh, FRCS, MB BCh, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Todd M. Morgan, MD, University of Michigan Health System, Ann Arbor; Jeff M. Holzbeierlein, MD, University of Kansas Medical Center, Kansas City; Trinity J. Bivalacqua, MD, PhD, University of Pennsylvania, Philadelphia; Scott North, MD, FRCPC, MHPE, Cross Cancer Institute, Edmonton, Alberta, Canada; Daniel A. Barocas, MD, MPH, FACS, Vanderbilt University Medical Center, Nashville, Tennessee; Petros Grivas, MD, PhD, University of Washington, Seattle, Fred Hutchinson Cancer Center, Seattle, Washington, University of Washington, Seattle; Jorge A. Garcia, MD, Case Comprehensive Cancer Center, Cleveland, Ohio; Andrew J. Stephenson, MD, Rush University, Chicago, Illinois; Jay B. Shah, MD, Stanford University, Palo Alto, California; Siamak Daneshmand, MD, USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles; Philippe E. Spiess, MD, MS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Bas W. G. van Rhijn, MD, PhD, Netherlands Cancer Institute, Amsterdam, Caritas St Josef Medical Center, University of Regensburg, Germany; Laura Mertens, MD, Netherlands Cancer Institute, Amsterdam; Peter Black, MD, FACS, FRCSC, University of British Columbia, Vancouver, Canada; Jonathan L. Wright, MD, MS, FACS, University of Washington, Seattle, Fred Hutchinson Cancer Center, Seattle, Washington | Posted on: 18 May 2023